Announcements - OBI Pharma 台灣浩鼎

2021.May.13

OBI-999 completes its Phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to Phase 2 as planned

2021.May.07

Supplementary statement for 2021 shareholders’ meeting (additional matters)

2021.May.07

Announcement that the consolidated financial statements for the first quarter of 2021 were authorized for issuance by the Board of Directors

2021.May.07

Updates on the planned allocation of the cash raised from the 2018 fundraising

2021.May.06

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study

2021.May.05

OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned

2021.Apr.29

Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company's Board of Directors resolved to convene the 2021 Annual General Shareholders' Meeting

2021.Apr.29

Announcement of the resolution by the Board of Directors not to distribute dividends by the company, on behalf of major subsidiary Amaran Biotechnology, Inc.

2021.Apr.21

OBI-3424 completes its phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to phase 2 as planned

2021.Apr.20

OBI Filed the Application of Phase III Human Clinical Study for the Active Cancer Immunotherapy OBI-822, Adagloxad Simolenin, to the Health Authority of Peru

News

Latest News

Events

Latest events